Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMN AMN Healthcare Services	$21.06 -2.9%	$20.87	$17.45 ▼ $70.07	$830.78M	0.19	893,693 shs	642,995 shs
BPMC Blueprint Medicines	$128.25 0.0%	$107.53	$73.04 ▼ $128.45	$8.28B	0.84	1.28 million shs	2.44 million shs
INDV Indivior	$13.73 -1.4%	$11.96	$7.33 ▼ $16.61	$1.92B	0.66	1.12 million shs	854,131 shs
LTH Life Time Group	$29.16 -1.8%	$29.50	$18.24 ▼ $34.99	$6.52B	1.75	1.92 million shs	3.05 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMN AMN Healthcare Services	+2.42%	-1.28%	+4.23%	-7.78%	-59.45%
BPMC Blueprint Medicines	-0.11%	+0.02%	+26.36%	+41.38%	+20.89%
INDV Indivior	-0.22%	+1.09%	+23.62%	+43.65%	-16.25%
LTH Life Time Group	+0.70%	+11.80%	+2.68%	-6.42%	+63.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMN AMN Healthcare Services	4.255 of 5 stars	3.1	2.0	4.3	2.3	1.7	1.9
BPMC Blueprint Medicines	1.1781 of 5 stars	2.1	2.0	0.0	2.6	0.8	0.6
INDV Indivior	2.401 of 5 stars	1.6	5.0	0.0	2.3	1.7	1.9
LTH Life Time Group	2.0558 of 5 stars	2.3	2.0	0.0	1.3	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMN AMN Healthcare Services	2.25	Hold	$32.08	52.34% Upside
BPMC Blueprint Medicines	2.27	Hold	$128.06	-0.15% Downside
INDV Indivior	3.25	Buy	$15.00	9.25% Upside
LTH Life Time Group	2.62	Moderate Buy	$35.92	23.19% Upside

Current Analyst Ratings Breakdown

Latest AMN, INDV, BPMC, and LTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	LTH Life Time Group	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
6/18/2025	LTH Life Time Group	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMN AMN Healthcare Services	$2.98B	0.27	$13.33 per share	1.58	$18.56 per share	1.13
BPMC Blueprint Medicines	$508.82M	16.28	N/A	N/A	$4.70 per share	27.29
INDV Indivior	$1.19B	N/A	$1.79 per share	7.65	($2.52) per share	N/A
LTH Life Time Group	$2.62B	2.44	$2.11 per share	13.85	$12.61 per share	2.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMN AMN Healthcare Services	-$146.98M	-$4.33	N/A	8.70	N/A	-5.80%	13.39%	4.17%	8/6/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.31	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
INDV Indivior	$2M	-$0.31	N/A	8.03	N/A	-4.02%	-97.29%	15.74%	7/24/2025 (Estimated)
LTH Life Time Group	$156.24M	$0.96	30.38	27.77	N/A	7.60%	8.29%	2.96%	8/7/2025 (Estimated)

Latest AMN, INDV, BPMC, and LTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	AMN AMN Healthcare Services	$0.19	$0.45	+$0.26	-$0.03	$670.08 million	$689.53 million
5/8/2025	Q1 2025	LTH Life Time Group	$0.27	$0.39	+$0.12	$0.34	$684.06 million	$706.04 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million
4/24/2025	Q1 2025	INDV Indivior	$0.22	$0.41	+$0.19	$0.38	$240.13 million	$266.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMN AMN Healthcare Services	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
LTH Life Time Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMN AMN Healthcare Services	1.39	1.08	1.08
BPMC Blueprint Medicines	1.01	2.80	2.75
INDV Indivior	N/A	0.88	0.72
LTH Life Time Group	0.55	0.43	0.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMN AMN Healthcare Services	99.23%
BPMC Blueprint Medicines	N/A
INDV Indivior	60.33%
LTH Life Time Group	79.40%

Insider Ownership

Company	Insider Ownership
AMN AMN Healthcare Services	0.93%
BPMC Blueprint Medicines	4.21%
INDV Indivior	N/A
LTH Life Time Group	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMN AMN Healthcare Services	2,968	38.28 million	37.93 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
INDV Indivior	1,051	N/A	N/A	Not Optionable
LTH Life Time Group	43,800	219.42 million	200.33 million	Optionable

AMN, INDV, BPMC, and LTH Headlines

Recent News About These Companies

Life Time Closes on $150 Million Sale-Leaseback Transaction

June 25 at 2:56 AM | sgbonline.comS

Life Time Group's (LTH) "Buy" Rating Reaffirmed at Guggenheim

June 24 at 9:03 AM | marketbeat.com

HSAs for Gym Memberships? These 3 Fitness Stocks Could Soar (LTH)

...

June 24 at 7:13 AM | marketbeat.com

Life Time Closes on $150 Million Sale-Leaseback Transaction; Credit Rating Upgraded by S&P

June 23 at 5:26 PM | prnewswire.com

Life Time Group Holdings: Drop Some Weight And Go Overweight

June 23 at 12:43 PM | seekingalpha.com

Life Time Signs Landmark Lease at 10 Bryant Bringing New Wellness Destination to Midtown Manhattan

June 23 at 5:03 AM | prnewswire.com

GAMMA Investing LLC Grows Position in Life Time Group Holdings, Inc. (NYSE:LTH)

June 21, 2025 | marketbeat.com

Life Time Group (NYSE:LTH) Earns "Buy" Rating from Guggenheim

June 19, 2025 | americanbankingnews.com

Guggenheim Reiterates "Buy" Rating for Life Time Group (NYSE:LTH)

June 18, 2025 | marketbeat.com

Life Time Group (NYSE:LTH) Trading Down 5% Following Insider Selling

June 18, 2025 | americanbankingnews.com

Life Time Group (NYSE:LTH) Shares Down 5% Following Insider Selling

June 17, 2025 | marketbeat.com

Life Time Group Holdings, Inc. (NYSE:LTH) EVP Parham Javaheri Sells 84,744 Shares

June 17, 2025 | insidertrades.com

Life Time Group Holdings, Inc. (NYSE:LTH) EVP Sells $2,359,272.96 in Stock

June 16, 2025 | marketbeat.com

Life Time Group Holdings (LTH) Shares Cross Below 200 DMA

June 15, 2025 | nasdaq.com

Rhumbline Advisers Grows Position in Life Time Group Holdings, Inc. (NYSE:LTH)

June 15, 2025 | marketbeat.com

Life Time Group Holdings, Inc. (NYSE:LTH) Shares Bought by Park Avenue Securities LLC

June 13, 2025 | marketbeat.com

Insider Unloading: Erik Weaver Sells $517K Worth Of Life Time Group Hldgs Shares

June 11, 2025 | benzinga.com

Here's Why We Think Life Time Group Holdings (NYSE:LTH) Is Well Worth Watching

June 11, 2025 | finance.yahoo.com

Life Time's LTH Supplement Line Debuts Three New HYDRATE Electrolyte Flavors as National Hydration Month Kicks Off

June 11, 2025 | prnewswire.com

Insider Selling: Life Time Group Holdings, Inc. (NYSE:LTH) CFO Sells 18,000 Shares of Stock

June 11, 2025 | insidertrades.com

John G. Danhakl Sells 11,655,582 Shares of Life Time Group Holdings, Inc. (NYSE:LTH) Stock

June 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMN, INDV, BPMC, and LTH Company Descriptions

AMN Healthcare Services NYSE:AMN

$21.06 -0.64 (-2.95%)

Closing price 03:59 PM Eastern

Extended Trading

$21.04 -0.02 (-0.09%)

As of 04:20 PM Eastern

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.

Blueprint Medicines NASDAQ:BPMC

$128.25 -0.01 (-0.01%)

Closing price 04:00 PM Eastern

Extended Trading

$128.22 -0.03 (-0.02%)

As of 04:39 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Indivior NASDAQ:INDV

$13.73 -0.19 (-1.36%)

Closing price 04:00 PM Eastern

Extended Trading

$13.74 +0.01 (+0.07%)

As of 05:22 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Life Time Group NYSE:LTH

$29.16 -0.54 (-1.82%)

Closing price 03:59 PM Eastern

Extended Trading

$29.10 -0.07 (-0.22%)

As of 07:15 PM Eastern

Life Time Group Holdings, Inc. provides health, fitness, and wellness experiences to a community of individual members in the United States and Canada. It primarily engages in designing, building, and operating of sports and athletic, professional fitness, family recreation, and spa centers in a resort-like environment, principally in suburban and urban locations of metropolitan areas. The company also offers fitness floors with equipment, locker rooms, group fitness studios, indoor and outdoor pools, bistros, indoor and outdoor tennis courts, pickleball courts, basketball courts, LifeSpa, LifeCafe, and childcare and Kids Academy learning spaces. In addition, its Life Time Digital provides live streaming fitness classes, remote goal-based personal training, nutrition and weight loss support, curated award-winning health, and fitness and wellness content. The company is also involved in media activities, conducting athletic events, and provision of related services. It operates various centers, including ground leases. The company was formerly known as LTF Holdings, Inc. and changed its name to Life Time Group Holdings, Inc. in June 21, 2021. Life Time Group Holdings, Inc. was founded in 1992 and is headquartered in Chanhassen, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time